Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 5:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 352 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Sham Injection Procedure Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Randomized, Double-blind, Crossover, Pharmacokinetic (PK) and Glucodynamic (GD) Study of Continuous Subcutaneous Insulin Infusion (CSII) in Participants With Type 1 Diabetes Mellitus (T1DM)

NCT01275131
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin aspart, Recombinant human hyaluronidase PH20 (rHuPH20)
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jul 25, 2014 · Synced Oct 28, 2026, 5:35 PM EDT
Completed Phase 3 Interventional

A Study of rhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)

NCT00090623
View directory record Official record
Conditions
Macular Degeneration
Interventions
rhuFab V2 (ranibizumab)
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 21, 2013 · Synced Oct 28, 2026, 5:35 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of VV-14305 for the Treatment of Thyroid Eye Disease

NCT07404111
View directory record Official record
Conditions
Thyroid Eye Disease (TED)
Interventions
VV-14305, Sham (No Treatment)
Genetic · Other
Lead sponsor
Kriya Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Livonia, Michigan • Las Vegas, Nevada • Erie, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 28, 2026, 5:35 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA)

NCT02292537
View directory record Official record
Conditions
Spinal Muscular Atrophy
Interventions
Nusinersen, Sham procedure
Drug · Procedure
Lead sponsor
Biogen
Industry
Eligibility
2 Years to 12 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
11
States / cities
Los Angeles, California • Palo Alto, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Oct 28, 2026, 5:35 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Semaglutide on Nicotine Intake

NCT05530577
View directory record Official record
Conditions
Tobacco Use Disorder, Nicotine Addiction
Interventions
Semaglutide, Sham/placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
21 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 28, 2026, 5:35 PM EDT
Active, not recruiting Phase 3 Interventional

Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)

NCT06617429
View directory record Official record
Conditions
Angelman Syndrome
Interventions
GTX-102, Sham-LP
Drug · Procedure
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
4 Years to 17 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
14
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 28, 2026, 5:35 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

The Role of Platelet Rich Plasma for Erectile Dysfunction

NCT04357353
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
Platelet rich plasma, Placebo Sham Injection
Biological · Other
Lead sponsor
University of Nebraska
Other
Eligibility
50 Years to 80 Years · Male only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Oct 28, 2026, 5:35 PM EDT
Not listed Not applicable Interventional

Evaluation of the Tissue Genesis Icellator Cell Isolation System to Treat Erectile Dysfunction

NCT03518333
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
Injection of adipose derived cells into penis
Device
Lead sponsor
Tissue Genesis
Industry
Eligibility
21 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
San Diego, California • Washington D.C., District of Columbia • Gainesville, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Oct 28, 2026, 5:35 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion

NCT00168298
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
700 µg Dexamethasone, 350 µg Dexamethasone, Sham Injection
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
668 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 28, 2026, 5:35 PM EDT
Not listed Phase 2 Interventional

Study to Assess the Efficacy and Safety of Transplanting Autologous Skeletal Myoblasts, Into Infarcted Heart, Using an Catheter Delivery System

NCT00626314
View directory record Official record
Conditions
Ischemic Cardiomyopathy
Interventions
myoblast, sham
Biological
Lead sponsor
Mytogen, Inc.
Industry
Eligibility
21 Years to 75 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Gilbert, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 29, 2008 · Synced Oct 28, 2026, 5:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Regional Anesthesia (Supra-Orbital and Infra-Orbital Nerve Block) (SION) for Pain Management in Trans-sphenoidal Hypophysectomy

NCT04670614
View directory record Official record
Conditions
Post-operative Surgical Pain
Interventions
Nerve Block with ropivicaine 0.5% Injectable Solution, Nerve Block with Placebo sham control of 0.9% Normal Saline
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 28, 2026, 5:35 PM EDT
Completed Not applicable Interventional

Feasibility Study: Ulthera® System for the Treatment of Axillary Hyperhidrosis

NCT01713959
View directory record Official record
Conditions
Hyperhidrosis
Interventions
Ulthera System treatment, Sham treatment
Device
Lead sponsor
Ulthera, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Nov 24, 2017 · Synced Oct 28, 2026, 5:35 PM EDT
Completed Phase 3 Interventional Results available

Efficacy Study of GS010 for the Treatment of Vision Loss up to 6 Months From Onset in LHON Due to the ND4 Mutation

NCT02652767
View directory record Official record
Conditions
Optic, Atrophy, Hereditary, Leber
Interventions
GS010, Sham Intravitreal Injection
Biological · Device
Lead sponsor
GenSight Biologics
Industry
Eligibility
15 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Los Angeles, California • Atlanta, Georgia • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 28, 2026, 5:35 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.

NCT00605280
View directory record Official record
Conditions
Macular Edema Associated With Diabetes Mellitus
Interventions
Standard of Care, Macugen
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
28
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 28, 2026, 5:35 PM EDT
Completed Phase 1Phase 2 Interventional Results available

HORNBILL: A Study to Test Different Doses of BI 764524 in Patients Who Have Had Laser Treatment for a Type of Diabetic Eye Disease Called Diabetic Retinopathy With Diabetic Macular Ischemia

NCT04424290
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
BI 764524, Sham control of BI 764524
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
13
States / cities
Dothan, Alabama • Beverly Hills, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Oct 28, 2026, 5:35 PM EDT
Terminated Phase 2 Interventional Results available

Effects of Stellate Ganglion Block on Hot Flashes in Hispanic Women With Breast Cancer

NCT03122301
View directory record Official record
Conditions
Hot Flashes, Hot Flushes, Vasomotor Symptoms
Interventions
Stellate Ganglion Block injection with bupivicaine, Saline
Drug
Lead sponsor
Northwestern University
Other
Eligibility
30 Years to 70 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Oct 28, 2026, 5:35 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of TenoMiR in Lateral Epicondylitis

NCT06192927
View directory record Official record
Conditions
Tennis Elbow
Interventions
TenoMiR, 0.9% Sodium Chloride Injection
Drug
Lead sponsor
Causeway Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Redwood City, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 1, 2025 · Synced Oct 28, 2026, 5:35 PM EDT
Terminated Phase 3 Interventional Results available

Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO

NCT02980874
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
suprachoroidal CLS-TA, suprachoroidal sham, IVT aflibercept
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
58
States / cities
Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Oct 28, 2026, 5:35 PM EDT
Terminated Not applicable Interventional

Study of the Effect of Regional Nerve Blocks on Pain and Inflammation After Video Assisted Thorascopic Lung Surgery

NCT00639795
View directory record Official record
Conditions
Pain
Interventions
Thoracic Paravertebral Nerve Block
Procedure
Lead sponsor
Memorial Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Johnstown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 3, 2013 · Synced Oct 28, 2026, 5:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Intra-articular Pulsed Radiofrequency Neuromodulation Versus Intra-articular Steroids for Painful Knee Osteoarthritis

NCT04238598
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Pulse Radiofrequency, Standard of Care Intra- Articular Injection, Placebo Intra-Articular Injection
Procedure
Lead sponsor
Center For Interventional Pain and Spine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Exton, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 30, 2023 · Synced Oct 28, 2026, 5:35 PM EDT
Active, not recruiting Phase 3 Interventional

Moderate - Severe Degenerative Disc Disease Evaluation of the Lumbar Spine

NCT05516992
View directory record Official record
Conditions
Lumbar Degenerative Disc Disease
Interventions
SB-01 For Injection, Sham Needle
Drug
Lead sponsor
Spine BioPharma, Inc
Industry
Eligibility
18 Years and older
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • Napa, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Oct 28, 2026, 5:35 PM EDT
Terminated Phase 3 Interventional

Anecortave Acetate Risk-Reduction Trial (AART)

NCT00307398
View directory record Official record
Conditions
Dry AMD
Interventions
Anecortave Acetate (AL-3789) sterile suspension, 15 mg or 30 mg, Anecortave Acetate Vehicle
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
50 Years and older
Enrollment
2,596 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Nov 28, 2012 · Synced Oct 28, 2026, 5:35 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

NCT07215234
View directory record Official record
Conditions
Geographic Atrophy
Interventions
SAR446597, Sham Comparator
Drug
Lead sponsor
Sanofi
Industry
Eligibility
60 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
31
States / cities
Peoria, Arizona • Scottsdale, Arizona • Beverly Hills, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 28, 2026, 5:35 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis

NCT00333814
View directory record Official record
Conditions
Intermediate Uveitis, Posterior Uveitis
Interventions
dexamethasone, Sham injection
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2011 · Synced Oct 28, 2026, 5:35 PM EDT